A Phase 2 interventional study of Placebo and TAK-861 2 mg in Narcolepsy Type 2, sponsored by Takeda. Completed at 56 sites in 12 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-09.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Narcolepsy by Takeda — 4 open to participants now, 6 under way, 2 of them phase 3. Narcolepsy · Takeda.
Among the 16 studies in Narcolepsy by Takeda, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 6 in phase 2, and was the 7th registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →4 of the 16 studies in Narcolepsy by Takeda are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Australia, China and 4 more countries
Ages 18–70
Takeda · Sites in United States, China, France and 4 more countries
Ages 18–70
Takeda · Sites in United States, Australia, Finland and 9 more countries
Ages 16–70
Takeda
Ages 18–70
By country, each count listing its studies:
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 16 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 4
First in 2017; this study’s year is marked. 3 started in 2023.
This study's enrollment of 71 is close to the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 95 across the 12 interventional studies, 307 across the 4 observational. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
5 of the studies in Narcolepsy by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07363720Phase 3TakedaA Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy | 2026-12-17 |
| NCT06952699TakedaA Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) | 2026-11-30 |
| NCT07299097TakedaEpidemiology of Narcolepsy Type 1 and Type 2 in Spain | 2026-12-31 |
| NCT07903220TakedaA Study About Treatment Use in Adults With Narcolepsy Type 1 (NT1) in Europe and Canada | 2027-09-30 |
| NCT07633301TakedaA Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy) | 2027-11-28 |
Add all 5 to your calendar (.ics) → With an account.
Among the 16 studies in Narcolepsy by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of Wakefulness Test (MWT).
The study will enroll approximately 60 participants and they will be randomly assigned to 3 groups (20 per group) to take one of two different doses of TAK-861 or a placebo. All the participants will receive the treatment for 8 weeks. Participants will be asked to complete some questionnaires during the study. This trial will be conducted in North America, Europe, and Asia Pacific.
The drug being tested in this study is called TAK-861. TAK-861 is being tested to treat people who have narcolepsy without cataplexy [Narcolepsy Type 2 (NT2)]. This study will evaluate the efficacy, safety, and tolerability of 2 oral doses of TAK-861.
The study will enroll approximately 60 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
This is a multi-center trial to be conducted worldwide. The overall time to participate in this study is approximately 18 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: In Japan, participants aged 16 to 70 years, inclusive, may be included.
Note: If there is a potential participant with NT2 for whom a diagnostic nocturnal polysomnography (nPSG)/MSLT was performed more than 5 years ago or is not available, the site may repeat the diagnostic PSG/MSLT.
Exclusion Criteria:
The participant has one or more of the following psychiatric disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo tablets matching TAK-861, orally, twice daily (BID), from Days 1 to 56.
Drug: Placebo
Participants received TAK-861 2 mg, orally, BID, from Days 1 to 56.
Drug: TAK-861 2 mg
Participants received TAK-861 2 mg followed by the 5 mg dose, orally, from Days 1 to 56.
Drug: TAK-861 2 mg and 5 mg
TAK-861 placebo matching tablets.
TAK-861 2 mg tablets.
Drug page: Oveporexton
TAK-861 2 mg and 5 mg tablets.
Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8
The MWT is a validated, objective measure that evaluates a participant's ability to remain awake under soporific conditions for a defined period. During each MWT session (1 session = 40 minutes), participants were instructed to sit quietly and remain awake for as long as possible. Sleep latency in each session was recorded on EEG. If no sleep was observed according to these rules, then the latency was defined as 40 minutes. The linear mixed effects model for repeated measures (MMRM) was used for analysis.
Time frame: Baseline, Week 8
Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8
The ESS is a subjective, self-administered, validated scale (scored 0 to 3) to respond to each of the 8 questions of daily life that asks participants how likely they are to fall asleep in those situations. The scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range. The MMRM was used for analysis.
Time frame: Baseline, Week 8
Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug.
Time frame: From first dose of the study drug up to end of the study (up to 3 months)
Participants took part in the study at 28 investigative sites globally from 09 January 2023 to 25 December 2023.
| Milestone | Placebo | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg |
|---|---|---|---|
| Started | 24 | 23 | 24 |
| Completed | 21 | 19 | 22 |
| Not completed | 3 | 4 | 2 |
| Withdrew: Adverse event | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Reason not specified | 1 | 0 | 0 |
The MWT is a validated, objective measure that evaluates a participant's ability to remain awake under soporific conditions for a defined period. During each MWT session (1 session = 40 minutes), participants were instructed to sit quietly and remain awake for as long as possible. Sleep latency in each session was recorded on EEG. If no sleep was observed according to these rules, then the latency was defined as 40 minutes. The linear mixed effects model for repeated measures (MMRM) was used for analysis.
| minutes | Placebo | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg |
|---|---|---|---|
| Change From Baseline in the Average Sleep Latency as Determined From the MWT at Week 8 | 2.14 ± 2.246 | 1.90 ± 2.384 | 4.54 ± 2.300 |
The ESS is a subjective, self-administered, validated scale (scored 0 to 3) to respond to each of the 8 questions of daily life that asks participants how likely they are to fall asleep in those situations. The scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness, and scores below 10 are considered to be within the normal range. The MMRM was used for analysis.
| score on a scale | Placebo | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg |
|---|---|---|---|
| Change From Baseline in Epworth Sleepiness Scale (ESS) Total Score at Week 8 | -3.39 ± 1.140 | -3.71 ± 1.206 | -6.45 ± 1.121 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not the occurrence is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE whose date of onset occurred on or after the first dose of study drug.
| Participants | Placebo | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg |
|---|---|---|---|
| Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) | 8 | 10 | 18 |
Collected over From first dose of the study drug up to end of the study (up to 3 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/24 (0%) | 0/24 (0%) | 2/24 (8.3%) |
| TAK-861 2 mg BID | 0/23 (0%) | 0/23 (0%) | 7/23 (30.4%) |
| TAK-861 2 mg and 5 mg | 0/24 (0%) | 0/24 (0%) | 14/24 (58.3%) |
| Event | Placebo | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg |
|---|---|---|---|
| PollakiuriaRenal and urinary disorders | 0/24 | 3/23 | 8/24 |
| InsomniaPsychiatric disorders | 2/24 | 2/23 | 5/24 |
| Pharyngitis streptococcalInfections and infestations | 0/24 | 2/23 | 0/24 |
| HeadacheNervous system disorders | 0/24 | 0/23 | 2/24 |
| Micturition urgencyRenal and urinary disorders | 0/24 | 1/23 | 2/24 |
| Urinary incontinenceRenal and urinary disorders | 0/24 | 0/23 | 2/24 |
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | Total |
|---|---|---|---|---|
| Mean | 37.0 ± 12.69 | 34.9 ± 9.77 | 36.8 ± 12.61 | 36.2 ± 11.66 |
| Sex: Female, Male(Participants) | Placebo | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | Total |
|---|---|---|---|---|
| Female | 18 | 14 | 17 | 49 |
| Male | 6 | 9 | 7 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 5 | 2 | 13 |
| Not Hispanic or Latino | 18 | 18 | 20 | 56 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 3 | 3 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 1 | 5 | 13 |
| White | 13 | 19 | 14 | 46 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 2 | 3 |
| Average Sleep Latency From the Maintenance of Wakefulness Test (MWT)(minutes) | Placebo | TAK-861 2 mg BID | TAK-861 2 mg and 5 mg | Total |
|---|---|---|---|---|
| Mean | 10.8 ± 8.72 | 9.9 ± 10.29 | 8.4 ± 8.26 | 9.7 ± 9.04 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2023 to primary completion in Dec 2023, 11 months.
Results were first posted in Jan 2025, 1 year after primary completion.
Of 15 phase 2 interventional studies under Narcolepsy, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oveporexton